Menu Search
Equities

Medclair AB

MCLR:NGM

Medclair AB

Actions
  • Price (SEK)1.88
  • Today's Change0.015 / 0.80%
  • Shares traded172.77k
  • 1 Year change+45.06%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Medclair AB grew revenues 60.13% from 24.89m to 39.85m while net income improved from a loss of 5.00m to a smaller loss of 2.79m.
Gross margin61.65%
Net profit margin5.16%
Operating margin-5.78%
Return on assets3.88%
Return on equity4.64%
Return on investment4.64%
More ▼

Cash flow in SEKView more

In 2023, cash reserves at Medclair AB fell by 687.00k. However, the company earned 5.26m from its operations for a Cash Flow Margin of 13.20%. In addition the company used 5.45m on investing activities and also paid 493.00k in financing cash flows.
Cash flow per share0.101
Price/Cash flow per share19.24
Book value per share0.6486
Tangible book value per share0.2445
More ▼

Balance sheet in SEKView more

Medclair AB uses little debt in its capital structure as supported by a debt to capital ratio of 0.27%.
Current ratio1.88
Quick ratio1.42
Total debt/total equity0.0027
Total debt/total capital0.0027
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.